In vitro antimicrobial susceptibility in clinical isolates of Enterococcus species

Salud Publica de Mexico

Volumn 45, Issue 2, 2003, Pages 96-101

  Calderón Jaimes, Ernesto ^a   Arredondo García, José Luis ^b   Aguilar Ituarte, Felipe ^a,b   García Roca, Pilar ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

Drug resistance, microbial; Enterobacteriaceae infections; Mexico

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; PENICILLIN G; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE;

EID: 0037989071     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-36342003000200005     Document Type: Article

References (40)

1. Schaberg DR, Culver DH, Gaynes RP. Mayor trends in the microbial etiology of nosocomial infection. Am J Med 91;(suppl 3B):72S-75S.
2. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-599.
3. Tornieporth N, Roberts RB, John J, Hafnier A, Riley LW. Risk factors associated with vancomycin-resistant Enteracoccus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-772.
4. Edmond MB, Ober JF, Dawson JD, Weinbaurri DC, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 1996;23:1234-1239.
5. Eliopoulos GM. Vancomycin-resistant enterococci: Mechanism and clinical relevance. Infect Dis Clin North Am 1997;11:851-865.
6. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:45-65.
7. Rubin L, Tucci V, Cerenado E, Elioponlos G, Isenberg H. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-705.
8. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303-316.
9. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J et al. An analysis of 110 serious enterococcal Infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine 1995;74:191-200.
10. Ross TW. Infectious disease challenge: Vancomycin-resistant enterococcus and staphylococcus. Drug Topics 1998;142:76-83.
11. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997;102:284-293.
12. Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis 1998;4:37-47.
13. Gold HS. Vancomycin-resistant enterococci: Mechanisms and clinical observations. Clin Infect Dis 2001;33:210-219.
14. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg Infect Dis 1998;4:239-249.
15. Hodges TR, Zighelboim-Daum S, Eliopulus GM, Wennerstein CB. Moellering RC. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992;36:121-125.
16. Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-1199.
17. Gold HS, Moellering RC. Drug therapy: Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-1454.
18. Centinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707.
19. Perl TM. The threat of vancomycin resistance. Am J Med. 1999;106:26S-37S.
20. th ed. Washington, DC:American Society for Microbiology, 1999:297-305.
21. Facklam RR, Collin MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731-734.
22. th ed. Wayne (PA): NCCLS, 2000; Document M7-A-5, 27.
23. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelfth Informational Supplement. Wayne (PA): NCCLS, 2002; Document M100-S12.
24. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: An important infection control variable. Arch Intern Med 1998;158:1127-1132.
25. Palmer SM, Ryback MJ. Vancomycin-resistant enterocci. Pharmacotherapy 1996;16:819-829.
26. Miranda G, Lee L, Kelly C, Solórzano F, Leaños B, Muñoz O et al. Antimicrobial resistance from enterococci in a pediatric hospital. Plasmids in Enterococcus faecalis isolates with high-level gentamicin and streptomycin resistance. Arch Med Res 2001;32:159-163.
27. Sifuentes-Osornio J, Ponce deLeón A, Muñoz-Trejo T, Villalobos-Zapata Y, Ontiveros-Rodríguez C, Gómez-Roldan C. Antimicrobial susceptibility patterns and high-level gentamicin resistance among enterococci isolated in a Mexican tertiary care center. Rev Invest Clin 1996;48:91-96.
28. Pfaller MA, Jones RN, Doern GV, Kugler K, the SENTRY participants Group. Bacterial pathogens isolated from patients with blood stream infections: Frequencies of ocurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-1770.
29. Sader HS, Jones RN, Gales AC, Winokur P, Kugler KC, Pfaller MA et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: Analysis of results from the SENTRY. Antimicrobial Surveillance Program (1997), SENTRY Latin American Study Group. Diagn Microbiol Infect Dis 1998;32:289-301.
30. Gales AC, Jones RN, Pfaller MA, Gordon KA, Sader HS, Sampaio J et al. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Result from the SENTRY Antimicrobial Surveillance Program, 1997-98. Int J Infect Dis 2000;4:75-84.
31. Arthur M, Reynolds PE, Depardieu F, Corvalin P. Mechanisms of glycopeptide resistance in enterococci. J Infect Dis 1996;32:11-16.
32. Ferretti JJ, Gilmore KS, Courvaiin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6′-aminoglycoside acetyltransferase 2″-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J Bacteriol 1986;167:631-638.
33. Weinstein MP. Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 2001;39:2729-2731.
34. Herman DJ, Gerdin DN. Screening and treatment of infections caused by resistant enterococci. Antimicrob Agent Chemother 1991;35:215-219.
35. Quintiliani R, Evers S, Courvalin P. The van B gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993;167:1220-1223.
36. Garbutt J, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000;30:466-472.
37. Lautenback E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-323.
38. Lucas G, Lechtzin N, Puryear W, Yaul, Flexner C, Moore R. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127-1133.
39. Naskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-2062.
40. Clement D, Markham A. Linezolid. Drug 2000;59:815-827.